Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study
Open Access
- 1 February 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 12 (2) , 255-258
- https://doi.org/10.1023/a:1008336732273
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Topotecan treatment of adults with primary malignant gliomaCancer, 1999
- Salvage Chemotherapy with Taxol for Recurrent Anaplastic AstrocytomasJournal of Neuro-Oncology, 1999
- Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade gliomaCancer Chemotherapy and Pharmacology, 1997
- Effect of neurological dysfunction on health-related quality of life in patients with high-grade gliomaJournal of Neuro-Oncology, 1997
- The Role of Chemotherapy in Recurrent Malignant Gliomas: An OverviewCancer Investigation, 1996
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958